Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Z Li

Showing results (201-210 of 270) with videos related to

Pageof 27
Sort By:
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Open Forum Infectious Diseases|March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2023
High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II TrialRaffaele Di Fenza, Naman S Shetty, Stefano Gianni, et al.
Biorxiv : the Preprint Server for Biology|October 20, 2022
Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 OmicronDa-Yuan Chen, Devin Kenney, Chue-Vin Chin, et al.
The New England Journal of Medicine|September 16, 2020
Detection of SARS-CoV-2 with SHERLOCK One-Pot TestingJulia Joung, Alim Ladha, Makoto Saito, et al.
JCI Insight|February 8, 2024
Predictors of HIV rebound differ by timing of antiretroviral therapy initiationJonathan Z Li, Meghan Melberg, Autumn Kittilson, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Nature|January 11, 2023
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuationDa-Yuan Chen, Chue Vin Chin, Devin Kenney, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
Pageof 27

Showing results (201-210 of 270) with videos related to

Sort By:
Pageof 27
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Open Forum Infectious Diseases|March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2023
High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II TrialRaffaele Di Fenza, Naman S Shetty, Stefano Gianni, et al.
Biorxiv : the Preprint Server for Biology|October 20, 2022
Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 OmicronDa-Yuan Chen, Devin Kenney, Chue-Vin Chin, et al.
The New England Journal of Medicine|September 16, 2020
Detection of SARS-CoV-2 with SHERLOCK One-Pot TestingJulia Joung, Alim Ladha, Makoto Saito, et al.
JCI Insight|February 8, 2024
Predictors of HIV rebound differ by timing of antiretroviral therapy initiationJonathan Z Li, Meghan Melberg, Autumn Kittilson, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Nature|January 11, 2023
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuationDa-Yuan Chen, Chue Vin Chin, Devin Kenney, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
Pageof 27